Key result
Adding serum metabolomics to PCP-HF significantly improves incident heart failure risk prediction.
Why the study?
Does integrating 1H-NMR serum metabolomics with clinical risk models (PCP-HF or age and sex) improve risk stratification and prediction of incident heart failure compared to clinical risk models alone in adults without prior cardiovascular disease?
Cohort (n=68,311)
Yes
Does integrating 1H-NMR serum metabolomics with clinical risk models (PCP-HF or age and sex) improve risk stratification and prediction of incident heart failure compared to clinical risk models alone in adults without prior cardiovascular disease?
Serum 1H-NMR metabolomics improves 10-year incident heart failure risk discrimination beyond the validated PCP-HF clinical score, and a simplified model of age, sex, and metabolomics achieves comparable performance to complex multi-domain clinical risk scores.
Answers are grounded in this paper and cite their sources.
May refine primary prevention HF stratification; leaves open clinical adoption pending prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Oexner et al. (2024) conducted a cohort in Incident Heart Failure (n=68,311). Serum metabolomics (168 metabolites via 1H-NMR spectroscopy) added to Pooled Cohort Equations to Prevent HF (PCP-HF) vs. Pooled Cohort Equations to Prevent HF (PCP-HF) clinical risk score alone was evaluated on Incident heart failure (earliest occurrence of clinical diagnosis of HF in electronic health records or death by HF in death registers) (ΔHarrell's C 0.013, continuous NRI 0.287, relative IDI 17.47%, 95% CI 0.004-0.022, p=3.664e-8). Adding serum metabolomics to the PCP-HF clinical score improved incident heart failure risk prediction.
Synapse has enriched 10 related papers. Consider them for comparative context: